Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Sponsored by Alliance for Clinical Trials in Oncology
About this trial
Last updated 9 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 20 years ago
What is this trial about?
What are the Participation Requirements?
DISEASE CHARACTERISTICS:
- Diagnosis of T-cell large granular lymphocytic leukemia
- Increased numbers of large granular lymphocytes in peripheral blood smears
- CD3+CD8+CD57+ immunophenotype by flow cytometry AND
- CD3+CD57+ cell count at least 2,000/mm^3 OR
- CD3+CD57+ cell count at least 500/mm^3 with clonal T-cell receptor beta gene
rearrangement
- Patients must have at least 1 of the following:
- Severe neutropenia (absolute neutrophil count (ANC) less than 500/mm^3)
- Neutropenia (ANC less than 1,000/mm^3) and recurrent infections
- Anemia (hemoglobin less than 9 g/dL)
- Thrombocytopenia (platelet count less than 50,000/mm^3)
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- NCI CTC 0-3
Hematopoietic:
- See Disease Characteristics
Hepatic:
- Bilirubin no greater than 2 times upper limit of normal (ULN)
Renal:
- Creatinine no greater than 2 times ULN
Other:
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Endocrine therapy:
- No concurrent hormonal therapy except steroids for adrenal failure or hormones for
nondisease-related conditions (e.g., insulin for diabetes)
- No concurrent dexamethasone or other steroidal antiemetics
Other:
- No prior cyclosporine therapy for this leukemia